Xeglyze

Single application head lice product capable of killing both eggs and lice.

Intellectual Property

Hatchtech has a robust patent portfolio that provides exclusive rights to Xeglyze™ Lotion.

In part, Hatchtech's intellectual property estate arises from international applications PCT/AU04/00955 and PCT/IB07/003226. Issued patents have been obtained in Australia, Canada, China, India, Japan, New Zealand, South Africa, Europe and the United States.

Hatchtech's intellectual property estate includes patents to the use of the active component in Xeglyze™ and related compounds in inhibiting ectoparasite egg hatching and other life stages.

An exemplary patent of Hatchtech’s IP portfolio is U.S. Patent 7,812,163, which affords the Company patent protection in the United States until October 2026.

Hatchtech has a strong commitment to its intellectual property portfolio and continues to pursue other avenues of patent protection.

Latest News

Oct 21, 2014 Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results

Dec 11, 2013 Hatchtech Receives SPA and Announces Patent Grants

Oct 31, 2013 Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission